{"analyses":[{"ciLowerLimit":"0.82","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.19","estimateComment":"Stratified by stage of disease (International Staging System 1 - 2 vs 3), age (\\<75 years old vs \\>= 75 years old) and ECOG performance status (0 vs 1 - 2) at randomization.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.8932","paramType":"Hazard Ratio (HR)","paramValue":"0.99","statisticalMethod":"Stratified log rank test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"52.76","upperLimit":"67.35","value":"60.42"},{"groupId":"OG001","lowerLimit":"48.95","upperLimit":"66.56","value":"57.56"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"374"}],"units":"Participants"}],"description":"Survival is defined as the time from randomization to the date of death. A participant who did not die had his or her survival duration censored at the date of last contact ('last known date alive\").","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants receiving a combination of Elotuzumab (E) Lenalidomide (L) Dexamethasone (d) in a 28 day cycle","id":"OG000","title":"E-Ld Cohort"},{"description":"Participants receiving a combination of Lenalidomide (L) Dexamethasone (d) in a 28 day cycle","id":"OG001","title":"Ld Cohort"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to the date of death (up to 8 years)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}